We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Official Warns of Bioequivalence Deficiencies in ANDAs
FDA Official Warns of Bioequivalence Deficiencies in ANDAs
Generic drug applicants need to get their bioanalytics right when demonstrating bioequivalence to avoid costly delays or outright rejection by the FDA, an agency official warns.